STA 9090

Known as: Hsp90 Inhibitor STA-9090, STA-9090, STA9090 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
024620082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Background Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in… (More)
Is this relevant?
2012
2012
This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling… (More)
Is this relevant?
2011
2011
There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations… (More)
  • figure 2
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?
2011
2011
7500 Background: Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation… (More)
Is this relevant?
2011
2011
10011 Background: Ganetespib, a potent, synthetic small-molecule inhibitor of Hsp90, has shown an improved safety profile… (More)
Is this relevant?
2011
2011
3051 Background: Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation… (More)
Is this relevant?
Review
2010
Review
2010
STA-9090 is a second-generation Hsp90 inhibitor in clinical development by Synta Pharmaceuticals for the intravenous treatment of… (More)
Is this relevant?
2008
2008
OBJECTIVE Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers. While Kit inhibitors have… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?